Melanoma International Collaboration for Adaptive Trials (MICAT)
Transforming the development of melanoma therapies
What if there was a better way to do drug research…
AIM’s Melanoma International Collaboration for Adaptive Trials (MICAT) wants to change the way we conduct melanoma clinical trials. We need to find answers faster, with greater precision, so that more patients can be successfully treated.
A smarter approach to drug research
MICAT uses an adaptive trial design to test new drugs on patients whose previously treated melanoma has spread. Rather than testing one drug at a time vs. the standard of care, MICAT simultaneously investigates multiple treatments using fewer patients by relying on dynamic data analysis to drive design in real time. MICAT will get the right drug to the right patient at the right time—and MICAT will do this faster than traditional clinical trials do.
Faster answers for tough questions
The stakes are high so we set the bar even higher. MICAT is working to discover:
- How to match the right treatment to the right patient
- What treatments are most likely to increase survival
- Which treatments should be used first? Second? Third?
- How biomarkers can guide treatment options
Combining forces to forge change
This is a group effort. AIM has brought together academic, regulatory, and industry partners to accelerate the approval of effective melanoma treatments.
- AIM at Melanoma
- IMWG (International Melanoma Working Group, an initiative of AIM)
- Pharmaceutical Product Development, LLC
- Berry Consultants
- RA Capital
- Industry partners
How you can help
MICAT is seeking support for this groundbreaking crusade to a CURE. To learn how you can help transform the discovery of effective treatments, contact Alicia Rowell, Vice President, AIM at Melanoma at Alicia@AIMatMelanoma.org.